Cargando…

CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups: An Autoantigenomic Approach

OBJECTIVE: To discover systemic characteristics in the repertoires of targeted autoantigens in chronic inflammatory demyelinating polyneuropathy (CIDP), we detected the entire autoantigen repertoire of patients and controls and analyzed them systematically. METHODS: We screened 43 human serum sample...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moritz, Christian P., Tholance, Yannick, Stoevesandt, Oda, Ferraud, Karine, Camdessanché, Jean-Philippe, Antoine, Jean-Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862091/ https://www.ncbi.nlm.nih.gov/pubmed/33408168 http://dx.doi.org/10.1212/NXI.0000000000000944

Ejemplares similares

Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies
por: Moritz, Christian P., et al.
Publicado: (2022)

Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases
por: Do, Le-Duy, et al.
Publicado: (2021)

The pattern and diagnostic criteria of sensory neuronopathy: a case–control study
por: Camdessanché, Jean-Philippe, et al.
Publicado: (2009)

COVID-19 and Guillain-Barré syndrome: Response()
por: Camdessanché, Jean-Philippe, et al.
Publicado: (2020)

The comparison of MRN, electrophysiology and progression among typical CIDP and atypical CIDP subtypes
por: Feng, Yuan, et al.
Publicado: (2020)

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins
por: Querol, Luis, et al.
Publicado: (2015)

The Misdiagnosis of CIDP: A Review
por: Allen, Jeffrey A.
Publicado: (2020)

Treatment Approaches for Atypical CIDP
por: Menon, Deepak, et al.
Publicado: (2021)

Severe CIDP-MGUS responsive to Rituximab
por: Posa, Andreas, et al.
Publicado: (2020)

CIDP mimics: a case series
por: Moshe-Lilie, Orly, et al.
Publicado: (2021)

Two CIDP Variants Patients With Anti-Caspr1 Antibodies in South China
por: Li, Chong, et al.
Publicado: (2022)

COVID-19 may induce Guillain–Barré syndrome
por: Camdessanche, J.-P., et al.
Publicado: (2020)

MRI biomarkers of proximal nerve injury in CIDP
por: Lichtenstein, Thorsten, et al.
Publicado: (2017)

Progress in Hematopoietic Stem Cell Transplantation for CIDP
por: Qin, Zhen, et al.
Publicado: (2020)

Editorial: Update on the Diagnosis and Management of CIDP Variants
por: Chroni, Elisabeth, et al.
Publicado: (2021)

The neurophysiological lesson from the Italian CIDP database
por: Spina, Emanuele, et al.
Publicado: (2021)

Terminal complement activation is increased and associated with disease severity in CIDP
por: Quast, Isaak, et al.
Publicado: (2016)

Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP)
por: Joshi, Abhijeet R., et al.
Publicado: (2016)

Deregulated Fcγ receptor expression in patients with CIDP
por: Quast, Isaak, et al.
Publicado: (2015)

CIDP prognosis in patients with IVIG treatment‐related fluctuations
por: Cook, Melissa, et al.
Publicado: (2022)

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
por: Merkies, Ingemar S.J., et al.
Publicado: (2019)

Nerve pathologic features differentiate POEMS syndrome from CIDP
por: Piccione, Ezequiel A., et al.
Publicado: (2016)

NK cell markers predict the efficacy of IV immunoglobulins in CIDP
por: Mausberg, Anne K., et al.
Publicado: (2020)

Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP
por: Querol, Luis, et al.
Publicado: (2021)

Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
por: Łukawska, Małgorzata, et al.
Publicado: (2021)

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

A Case of Relapsing - Remitting CIDP with Sixth Nerve Palsy
por: Thelengana, Arikrishnan, et al.
Publicado: (2021)

CIDP/autoimmune nodopathies with nephropathy: a case series study
por: Tang, Yuwei, et al.
Publicado: (2023)

Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype
por: Cortese, Andrea, et al.
Publicado: (2019)

Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination
por: Abraham, Alon, et al.
Publicado: (2015)

The economic burden of CIDP in the United States: A case-control study
por: Divino, Victoria, et al.
Publicado: (2018)

Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP
por: Markvardsen, Lars Kjøbsted, et al.
Publicado: (2019)

Abnormality of multimodal evoked potentials in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
por: Dziadkowiak, Edyta, et al.
Publicado: (2020)

The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP
por: Burt, Richard K., et al.
Publicado: (2021)

Corrigendum: Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
por: Łukawska, Małgorzata, et al.
Publicado: (2022)

Pathophysiology of the Different Clinical Phenotypes of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
por: Dziadkowiak, Edyta, et al.
Publicado: (2021)

Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients
por: Athanasopoulos, Diamantis, et al.
Publicado: (2021)

Neurophysiological Hallmarks of Axonal Degeneration in CIDP Patients: A Pilot Analysis
por: Ricciardi, Dario, et al.
Publicado: (2022)

CIDP: a multi-functional platform for designing CRISPR sgRNAs
por: Xu, Dong, et al.
Publicado: (2023)

Sensory and motor neuronopathy in a patient with the A382P TDP-43 mutation
por: Camdessanché, Jean-Philippe, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vc1kb87gqeerlh715ah30roo5b